Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CytomX Therapeutics (CTMX) Short-term Investments (2016 - 2025)

CytomX Therapeutics (CTMX) has disclosed Short-term Investments for 11 consecutive years, with $109.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Short-term Investments rose 42.11% year-over-year to $109.4 million, compared with a TTM value of $109.4 million through Sep 2025, up 42.11%, and an annual FY2024 reading of $62.6 million, down 60.23% over the prior year.
  • Short-term Investments was $109.4 million for Q3 2025 at CytomX Therapeutics, roughly flat from $109.0 million in the prior quarter.
  • Across five years, Short-term Investments topped out at $168.1 million in Q3 2023 and bottomed at $5000.0 in Q3 2021.
  • Average Short-term Investments over 5 years is $92.6 million, with a median of $99.1 million recorded in 2022.
  • The sharpest move saw Short-term Investments plummeted 100.0% in 2021, then skyrocketed 1984980.0% in 2022.
  • Year by year, Short-term Investments stood at $99.7 million in 2021, then fell by 0.44% to $99.3 million in 2022, then soared by 58.52% to $157.3 million in 2023, then tumbled by 60.23% to $62.6 million in 2024, then skyrocketed by 74.91% to $109.4 million in 2025.
  • Business Quant data shows Short-term Investments for CTMX at $109.4 million in Q3 2025, $109.0 million in Q2 2025, and $32.3 million in Q1 2025.